Xconomy: Arcus Bio Pulls Off IPO, Raises $120M for Cancer … – Xconomy
Xconomy |
Xconomy: Arcus Bio Pulls Off IPO, Raises $120M for Cancer …
Xconomy Arcus Biosciences has raised $120 million from an initial public offering as the cancer immunotherapy developer looks ahead to reporting its first clinical. Cancer-fighting Arcus (NYSE: RCUS), backed by Alphabet's GV … |
